AQTAYO

Serial Number 98073591
606

Registration Progress

Application Filed
Jul 6, 2023
Under Examination
Dec 19, 2023
Approved for Publication
Oct 24, 2023
Published for Opposition
Oct 24, 2023
Registered

Trademark Image

AQTAYO

Basic Information

Serial Number
98073591
Filing Date
July 6, 2023
Published for Opposition
October 24, 2023
Abandonment Date
January 20, 2025
Drawing Code
4

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Jan 20, 2025
Classes
005

Rights Holder

Cytokinetics, Incorporated

03
Address
350 Oyster Point Blvd.
South San Francisco, CA 94080

Ownership History

Cytokinetics, Incorporated

Original Applicant
03
South San Francisco, CA

Cytokinetics, Incorporated

Owner at Publication
03
South San Francisco, CA

Legal Representation

Attorney
B. Brett Heavner

USPTO Deadlines

All Deadlines Cleared

All 2 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

14 events
Date Code Type Description Documents
Jan 20, 2025 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Loading...
Jan 20, 2025 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Jan 9, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jan 5, 2024 EX1G S SOU EXTENSION 1 GRANTED Loading...
Jan 5, 2024 EXT1 S SOU EXTENSION 1 FILED Loading...
Jan 5, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Dec 19, 2023 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Oct 24, 2023 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Oct 24, 2023 PUBO A PUBLISHED FOR OPPOSITION Loading...
Oct 4, 2023 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Sep 18, 2023 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Sep 12, 2023 DOCK D ASSIGNED TO EXAMINER Loading...
Aug 6, 2023 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jul 10, 2023 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
human pharmaceuticals for the prevention, diagnosis, and treatment of cardiovascular diseases and conditions; pharmaceutical preparations to treat hypertrophic cardiomyopathies, heart failure, and heart failure with preserved ejection fraction

Classification

International Classes
005